Compare LUNR & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LUNR | KARD |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 525 | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | LUNR | KARD |
|---|---|---|
| Price | $12.34 | $20.81 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $22.35 | N/A |
| AVG Volume (30 Days) | ★ 7.9M | 270.1K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $343.00 | N/A |
| Revenue Next Year | $16.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.78 | $19.58 |
| 52 Week High | $46.75 | $27.00 |
| Indicator | LUNR | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 46.08 |
| Support Level | $10.49 | $20.91 |
| Resistance Level | $22.25 | $22.13 |
| Average True Range (ATR) | 0.95 | 1.73 |
| MACD | 0.23 | -0.17 |
| Stochastic Oscillator | 19.30 | 28.78 |
Intuitive Machines Inc is a space infrastructure and services company focused on enabling sustained human activity beyond Earth. It designs, builds, integrates, and operates space systems, offering infrastructure-as-a-service across low Earth orbit, geostationary orbit, cislunar space, and deep space. Its capabilities include spacecraft development and space-based network connectivity, serving commercial, civil, and national security customers. The company conducts sales both directly and through an extensive customer and partner network spanning North America, South America, Europe, Asia, and Australia, including rideshare delivery providers, lunar surface mobility providers, payload providers, communication satellite providers, and ground segment providers.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.